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Abstract
PURPOSE: Patients with non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)–mutations
have excellent response to EGFR tyrosine kinase inhibitors (TKIs), and exon 20 mutation accounts for most of TKI
drug resistance. Nested polymerase chain reaction (PCR) was used to detect EGFR exon 20 mutations of patients
with NSCLC after chemotherapy. The same is being analyzed with patients’ characteristics. METHODS: Peripheral
blood samples were collected from 273 patients with NSCLC, including 143 with adenocarcinoma (ADC) and 130
with squamous cell carcinoma (SCC), after chemotherapy. DNA was extracted from whole blood for nested PCR
amplification and purification. Sequencing was carried out in an automated 3730 sequencer, followed by analysis
of EGFR exon 20mutations from nested PCR products. RESULTS: Themutations of EGFR exon 20weremainly point
mutations in rs1050171 (c.2361A>G) and rs56183713 (c.2457G>A). The point mutation was 28.21%, 28.46%, and
27.97% in patients with NSCLC, ADC and SCC, respectively. Men had an equivalent mutation (27.18%) to women
(30.77%). The mutation in smokers and nonsmokers was 27.68% and 29.17%, respectively. In unselected patients,
there was no correlation between EGFR exon 20 mutations and patients’ characteristics of age, gender, smoking
history, histologic type, or tumor-node-metastasis (TNM) staging system. In subgroup analyses, the EGFR mutation
of patients with SCC was correlated with TNM stage [P = .013; odds ratio = 1.758; 95% confidence interval (CI) =
1.125-2.747]. CONCLUSIONS: The data indicate that the chemotherapy may induce EGFR-TKI–resistant mutation in
NSCLC cells and EGFR-TKI should be used in the early stage of NSCLC but not after chemotherapy.
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Introduction
Lung cancer is the leading cause of cancer death in the United States
[1] and China [2]. Non–small cell lung cancer (NSCLC) is the most
common histologic type, which affects approximately 80% to 85%
of all patients with lung cancer. Although much progress has been
made in the last 10 years for lung cancer (e.g., screening, minimally
invasive techniques for diagnosis and treatment, and targeted therapy)
[3], only 15.9% of all lung cancer patients can be alive for 5 years or
longer after diagnosis [4]. Because more than 70% of patients with
lung cancer are diagnosed with advanced-stage disease, systemic
treatment plays main role in clinical management. However, routine
platinum-based chemotherapy prolongs median survival time by only
a few months in these patients compared with supportive care.
Currently, median survival time is about 8 to 18 months for patients
with metastatic and locally advanced diseases, respectively [5].
Epidermal growth factor receptor (EGFR) is a transmembrane
receptor that is detectable in approximately 80% to 85% of patients
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with NSCLC, and the level of expression varies widely on a continual
scale. The activation of EGFR pathways results in the initiation of cancer
proliferation, increased metastasis potential, and neoangiogenesis.
In recent years, selective EGFR tyrosine kinase inhibitor (TKI) has
emerged as an alternative treatment option for advanced NSCLC.
Both erlotinib and gefitinib have demonstrated clinical efficacy in
the second- or third-line treatment of NSCLC, especially among
never smokers, females, East Asians, and adenocarcinoma (ADC) cell
type [6–9]. However, despite the fact that the majority of patients
with EGFR mutations benefited from these drugs, in excess of 20%
of patients experienced resistance and all tumors ultimately developed
resistance following initial response [10]. This is because EGFR
mutations are more common in patients who are Asian, female, non-
smokers, and have ADC [11–15], all mentioned characteristics being
linked to the known clinical predictors of gefitinib sensitivity [16–19].
Inhibition of EGFR kinase activities by EGFR-TKI, such as gefi-
tinib and erlotinib, results in effective treatment for patients with
NSCLC [6,20,21]. The IRESSA Pan-Asia Study clinical trial in Asia
and randomized controlled studies on advanced NSCLC have con-
firmed EGFR-activating mutations as the main predictor of clinical
outcome with TKI therapy [7,22,23]. The most commonly EGFR-
activating mutations were in exon 19 (Del19) and exon 21 (L858R)
that were found in approximately 10% of Caucasian patients with
NSCLC and up to 50% of Asian patients [24].
Other drug-sensitive mutations include point mutations at exon
21 and exon 18 [25]. The pretreatment EGFR T790M mutation
was associated with shorter progression-free survival (PFS) compared
to EGFR-TKI therapy in patients with NSCLC [26]. The mutation
play an important role in predicting PFS in patients with NSCLC and
EGFR-activating mutation treated with TKI [27]. The prevalence of
reported de novo T790M varied from 1% to 38% [27–30]. Han et al.
[31] found that EGFR mutations were detected in 39.4% (13/33)
and 54.5% (18/33) of the serum samples of pre-chemotherapy and
post-chemotherapy, respectively. Data show that PFS is improved
with use of EGFR-TKI in patients with EGFR mutations when com-
pared with standard chemotherapy, although overall survival is not
statistically different [32].
Primary resistance to TKI therapy is associated with mutation at
exon 20 [33–35]. However, the role of EGFR exon 20 mutations in
lung cancer progression, especially when it is present before TKI
treatment, is still being debated and lacks systematic exploration.
In mainland China, “adenocarcinoma” and “nonsmoker” were inde-
pendent predictors for EGFR mutations in exons 18, 19, and 21 [36],
while the correlation between EGFR exon 20 mutations and patients’
characteristics remains unclear. The purpose of this study is to detect
the relationship between EGFR exon 20 mutations and patients’ char-
acteristics in mainland China.
Patient and Methods
Patient Population
To be eligible for the study, patients were required to have path-
ologically confirmed stage NSCLC [either ADC or squamous cell
carcinoma (SCC)], Eastern Cooperative Oncology Group perfor-
mance status of 0 to 2, and available plasma. Only patients treated
at the Zhejiang Cancer Hospital from May 2012 to December 2012
were enrolled. Exclusion criteria included history of previous primary
cancer other than lung cancer and independent of other lung-related
disease, justifying this to avoid any probable interference from over-
lapping genes. All subjects provided their informed consent, and the study
was approved by the ethics committee of Zhejiang Cancer Hospital.
DNA Preparation and Sequencing
DNA was isolated from whole blood by using the AxyPrep Blood
Genomic DNAMiniprep Kit (Axygen Biosciences, Union City, CA).
A two-step “boost/nest” polymerase chain reaction (PCR) strategy
was employed where the boost reaction generated a larger fragment
used as a template for the nest reaction. The nest products were bi-
directionally sequenced on ABI 3730 XL sequencers (ABI Company,
Oyster Bay, NY) with ABI BigDye Terminator v3.1 chemistry. Base
calling was performed by the Agent system (Paracel, Alameda, CA).
Sequence tracings were visually inspected to confirm accurate variant
detection by the base-calling software. Coding variants were confirmed
on repeat PCRs to exclude PCR artifacts. GenBank NM_201283 was
used as the reference cDNA for nucleotide positions.
Nested PCR Amplification and Purification
Primer sequences for EGFR exon 20–nested PCR and extension
were designed by using the Assay Designers Software version 3.0
(Sequenom, San Diego, CA) and were processed following standard
protocols for iPLEX chemistry. Primers were synthesized by Sangon
Biotech (Shanghai, China). Primer sequences for boost PCR (502 bp)
were forward 5′-TGACTCCGACTCCTCCTTTA-3′ and reverse 5′-
ATCTCCCTTCCCTGATTAC-3′. Primer sequences for nest PCR
(365 bp) were forward 5′-GTCCCTGTGCTAGGTCTTTT-3′
and reverse 5′-ATCTCCCTTCCCTGAT-TAC-3′. The first PCR
assays were carried out in a 50-μl volume that contained 1 μl of extracted
DNA, 1 μl of primers (R1 and F1), and 0.5 μl of TaqDNA polymerase.
DNA was amplified for 35 cycles at 95°C for 3 minutes, 94°C for
30 seconds, 55 to 60°C for 35 seconds, 72°C for 40 to 50 seconds,
followed by a 5- to 8-minute repaired extension at 72°C. The second
PCRs were carried out in a 25-μl volume, including 2 μl of DNA from
the first PCR products, 0.3 μl of primers (R1 and F1), and 0.3 μl of
Taq DNA polymerase. DNA was amplified at 95°C for 5 minutes, the
next 35 cycles at 95°C for 30 seconds, 55°C for 35 seconds, 72°C for
30 seconds, followed by a 10-minute extension at 72°C. Nested PCR
products were electrophoresed in 1% agarose gel. Only PCR products
with a positive band were purified using PCR Product Purification Kit
(SanPrep, SK1141).
Sequencing Analysis
Before sequencing, PCR sequencing reaction for PCR products
was used by BigDye Terminator v1.1 Kit (Applied Biosystems, Foster
City, CA) and performed in the light of the kit’s request. All PCR
assays were carried out in a 20-μl volume, including 1 μl of purified
PCR products, 8 μl of BigDye (2.5×), and 1 μl of primers (3.2 pmol/μl).
PCR sequencing reaction was performed at 96°C for 1 minute, then
followed by 25 cycles at 96°C for 10 seconds, 50°C for 5 seconds,
and 60°C for 4 minutes. Sequencing was carried out in an ABI 3730
Genetic Analyzer (Applied Biosystems). All sequence variants were con-
firmed by sequencing the products of independent PCR amplifications.
Statistical Analysis
We used the χ2 to assess the relationship between EGFR exon 20
mutations and each of the clinical and pathologic parameters. The
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relationship between EGFR exon 20 mutations and demographic
characteristics was analyzed by logistic regression. The statistical anal-
ysis was performed using SPSS v13.0. All P values were two-sided,
and P < .05 was considered significant.
Results
Patients’ Characteristics
A total of 300 patients met the enrollment criteria and were enrolled
in the study. The patients consisted of 217 men and 83 women, all of
which accepted one to four cycles of platinum-based combined chemo-
therapy. There were 155 patients with lung ADC and 145 with SCC. A
total of 197 patients were smokers and 103 were nonsmokers. The
patients’ clinical and disease characteristics are listed in Table 1.
DNA was not available for 27 patients (20 males and 7 females), and
273 patients remained in the analysis list.
Relationship between EGFR Mutations
and Patients’ Characteristics
The EGFR exon 20 wild-type DNA sequence was GAAGCC-
TACGTGATGGC-CAGCGTGGACAACCCCCACG-
TGTGCCGCCTGCTGGGCATCTGCCTCACCT -
C C ACCGTGCAGCTCATCACGCAGCTCATGC -
CCTTCGGCTGCCTCCTGGAC-TATGTCCGGGAACACAA-
AGACAATATTGGCTCCCAGTACCTGCTCAACTG-
GTGTGTGCAGATCGCAAAG (189 bp; Figure 1).
Table 1. Patients’ Clinical and Disease Characteristics.
Variables No. of Patients (N = 300) Percentage of Patients
Age, years
Mean 58.20 –
SD 9.52 –
Sex
Male 217 72.33
Female 83 27.67
Smoking history
Smokers 199 66.33
Nonsmoker 101 33.67
Histologic type
ADC 155 51.67
SCC 145 48.33
Disease stage
I 15 5.00
II 23 7.67
III 100 33.33
IV 162 54.00
Figure 1. EGFR exon 20 wild-type DNA sequence.
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The mutations of EGFR exon 20 were mainly point mutations in
rs1050171 (c.2361A>G) and rs56183713 (c.2457G>A; Figure 2).
The results showed that the EGFR mutation was 28.21%, 28.46%,
and 27.97% in patients with NSCLC, ADC, and SCC, respectively.
Men had an equivalent mutation (27.18%) to women (30.77%).
The mutation in smokers and nonsmokers was 27.68% and 29.17%,
respectively.Differences between ADCand SCC,men andwomen, and
smokers and nonsmokers did not reach statistical significance (Table 2).
Multivariate analysis was performed to analyze correlation between
EGFR mutation and patients’ variables. The dependent variable was
EGFR status (mutant and wild type). The covariates included age
(years), gender (male and female), histology type (ADC and SCC),
Figure 2. Mutations of EGFR exon 20 rs1050171 and rs56183713.
Table 2. Association between EGFR Exon 20 Mutations and Clinicopathologic Parameters.
Item No. of Patients
with Mutation
No. of Patients
without Mutation
Age, years
≤60 44 119
>60 33 77
P .58
Sex
Male 53 142
Female 24 54
P .55
Smoking history
Smoker 49 128
Nonsmoker 28 68
P .79
Histologic type
ADC 40 103
SCC 37 93
P .93
Disease stage
I 5 9
P .52
II 7 9
P .15
III 22 70
P .26
IV 43 108
P .91
Table 3. Association between EGFR Exon 20 Mutations and Clinical Features in Patients
with NSCLC.
Parameter P Multivariate Analysis
OR 95% CI
Age .77 0.92 0.54-1.58
Sex .29 1.76 0.61-5.13
Smoking history .46 0.67 0.24-1.92
Histologic type .69 1.13 0.61-2.12
Disease stage .45 1.14 0.81-1.62
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smoking history (smoker and nonsmoker), and tumor-node-metastasis
(TNM) stage (I, II, III, and IV). There was no correlation between the
five variables and EGFR mutation (Table 3).
For its part, in subgroup analysis, multivariate analysis was used to
identify the correlation. In patients with SCC, the EGFR mutation
was correlated with TNM stage [P = .013; odds ratio (OR) = 1.758;
95% confidence interval (CI) = 1.125-2.747], but the three variables
(age, gender, and smoking history) were not correlated with EGFR
mutation (Table 4). In an almost equal way, in patients with ADC
the EGFR mutations were not correlated with age, gender, smoking
history, or TNM stage (Table 5).
Discussion
It has been confirmed that EGFR-activating mutations represents
the main predictor of clinical outcome with TKI therapy [7,22,23].
According to Hirsch and Bunn [24], the most commonly EGFR-
activating mutations are in exon 19 (Del19) and exon 21 (L858R).
Additionally, Riely et al. [25] indicated that other drug-sensitive muta-
tions include point mutations at exon 21 and exon 18. Primary resis-
tance to TKI therapy is associated with mutation at exon 20 [33–35].
However, the role of EGFR exon 20 mutations in lung cancer pro-
gression, especially its presence before TKI treatment, is still being
debated and lacks systematic exploration.
In this study, we found, in unselected patients with NSCLC treated
with platinum-based combined chemotherapy, that the EGFR exon 20
mutation was 28.21%, the same being 28.46% and 27.97% in ADC
and SCC, respectively. We failed to find the correlation between EGFR
exon 20 mutations and patients’ characteristics of age, gender, smoking
history, histologic type, or TNM stage. This may be ascribed to the
greatly increased EGFR-TKI–resistant mutation post-chemotherapy,
thus leading to the reduction of therapeutic effect of EGFR-TKI.
Therefore, if EGFR-TKI is used in NSCLC early stage, the benefits
that patients get from the drug will be maximized. Recent data also
suggest that erlotinib should be used as first-line systemic therapy in
patients with EGFR mutations documented before the mentioned
therapy [32,37–39]. Strikingly, we also found that the patients with
SCC had a higher TNM stage and more mutation (P = .013) in sub-
group analysis. These data indicated that the chemotherapy may induce
NSCLC cells to restrain EGFR-TKI. Thus, the higher the TNM stage,
the greater the resistance. These results suggest that the EGFR-TKI
should be used in the early stage ofNSCLC but not after chemotherapy.
It is also possible that mutation can be present before treatment
and mutation tumor cells may undergo a relatively indolent progression
in tumorigenesis [40–42]. De novo mutation might contribute to poor
survival besides the drug resistance [27].
Initially, EGFR exon 20 mutations were found in specimens of
NSCLC patients with EGFR-TKI treatment failure and currently
in untreated specimens. It is likely that primary tumor samples of
patients with NSCLC have significant de novo EGFR exon 20 muta-
tion and de novo TKI-resistant cells before TKI therapy. These TKI-
resistant clones grow in the selective environment of TKI therapy
because of their survival advantage [26]. Similarly, chemotherapy
can kill TKI-sensitive NSCLC cells, while TKI-resistant cells can
still grow.
It was reported that the specimens to detect EGFR mutation can
be derived from tissue, blood, and pleural fluid. Nevertheless, sequence
analysis of tumor DNA from tissue is still the most widely applied
method for detecting EGFRmutation and is considered the most direct
and reliable approach. In this study, we used peripheral blood to detect
EGFR exon 20 mutations. In the future, it is necessary to detect EGFR
mutations in both tissue and blood.
In conclusion, our data suggested that the platinum-based chemo-
therapy in this study can induce EGFR-TKI–resistant mutation in
NSCLC cells at EGFR exon 20 and that EGFR-TKI should be used
in the early stage of NSCLC but not after chemotherapy.
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